Large B-Cell Lymphoma
Author:
Bento Leyre,Glass Bertram,Schmitz Norbert
Abstract
AbstractThe most recent WHO classification of tumors of hematopoietic and lymphoid tissues (Alaggio et al. 2022) classifies large B cell lymphomas (LBCL) into diffuse large B cell lymphoma (DLBCL) NOS with distinct morphological and molecular (germinal center B-cell, activated B-cell) subtypes, high-grade B-cell lymphomas (with MYC and BCL2 rearrangements or NOS subtype), and other less frequent subtypes.
Publisher
Springer International Publishing
Reference29 articles.
1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng W-J, Choi JK, Chuang S-S, Coupland SE, Czader M, Dave SS, de Jong D, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. 2. Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas R-O, Mohty M, Guidez S, Joris M, Loschi M, Carras S, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28:2145–54. 3. Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, et al. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplant. 2021;56:1919–28. 4. Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349–58. 5. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–6.
|
|